
Inozyme Pharma Investor Relations Material
Latest events

Study Update
Inozyme Pharma

Q1 2025
13 May, 2025

Q4 2024
10 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Inozyme Pharma Inc
Access all reports
Inozyme Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases that affect the vasculature, soft tissue, and skeleton. The company's research is centered on disorders related to the PPi-Adenosine Axis, a pathway crucial for mineralization and vascular health. Disruptions in this pathway can lead to severe conditions such as ENPP1 and ABCC6 deficiencies, which Inozyme targets with its lead product candidate, INZ-701. This enzyme replacement therapy is designed to address pathologic mineralization and intimal proliferation, aiming to reduce the morbidity and mortality associated with these conditions. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.
Latest articles
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
)
Global Doughmination: Breaking Down Domino's Pizza
Inside the rise of Domino's Pizza: how franchising, delivery control, and supply chain mastery built one of the world's most efficient food empires.
18 Jul 2025
Ticker symbol
INZY
Country
🇺🇸 United States